What are you looking for?
top

Medicines

JAKAVI® (ruxolitinib)

JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1

Pink Background with an arrow
JAKAVI® (ruxolitinib) in myelofibrosis
JAKAVI® (ruxolitinib) in myelofibrosis
See more details
Hide details
Pink Background with an arrow
JAKAVI® (ruxolitinib) in polycythaemia vera
JAKAVI® (ruxolitinib) in polycythaemia vera
See more details
Hide details

Reference

  1. JAKAVI® (ruxolitinib) Summary of Product Characteristics.

UK | November 2024 | FA-11208694

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.